Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Thermo Fisher Scientific | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Thermo Fisher Scientific

Life Sciences Solutions Segment revenue up 9% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Thermo Fisher Scientific
2Q Revenues: $6.3 billion(+4%)
2Q Earnings: $1.1 billion (+49%)
YTD Revenues: $12.4 billion (+4%)
YTD Earnings: $1.9 billion (+45%)
Comments: The Life Sciences Solutions Segment revenue was up 9% to $1.7 billion in the quarter. Analytical Instruments Segment revenue grew 1% to $1.3 billion. Specialty Diagnostics Segment revenue increased 1% to $0.94 billion. Laboratory Products and Services Segment revenue grew 3% to $2.6 billion. Reported results in 2019 and 2018 include restructuring and other costs, consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Reported results in 2019 include a $505 million gain on the sale of the Anatomical Pathology business and $6 million of charges for impairment of acquired technology in development.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters